DOCSLIB.ORG

Free PDF Download

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Free PDF Download European Review for Medical and Pharmacological Sciences 2020; 24: 8429-8438 LINC00662 promotes cell proliferation, migration and invasion of melanoma by sponging miR-890 to upregulate ELK3 X.-Q. XIA1,2, W.-L. LU1,2, Y.-Y. YE3, J. CHEN1,2 1Department of Dermatology, Shanghai Ninth People’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China 2Department of Laser Cosmetology, Shanghai Ninth People’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China 3Department of Dermatology, Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No. 2 Hospital), Ningbo, China Abstract. – OBJECTIVE: Melanoma is one of Key Words: the most malignant types of skin tumors and LINC00662, MiR-890, ELK3, Melanoma. accounts for the majority of skin cancer-related deaths. LINC00662 is a tumor promoter in multi- ple types of cancer, but the role of LINC00662 in melanoma has not been fully elucidated. MATERIALS AND METHODS: The expres- Introduction sion levels of LINC00662, miR-890, and ELK3 were detected by Real Time-quantitative Poly- Melanoma is a malignant tumor which origi- merase Chain Reaction (RT-qPCR). MTT assay 1,2 was performed to measure the cell proliferation nated from melanocytes . Despite recent major ability in A375 and SK-MEL-1 cells. Cell mi- advances in tumor therapy, including surgery, gration and invasion abilities were measured radiotherapy and chemotherapy, the survival rate by wound healing assay and transwell assay, for patients with melanoma is still unsatisfacto- respectively. Besides, Luciferase reporter as- ry3,4. Accordingly, the study of novel molecular say was employed to examine the interaction targets in melanoma is an important challenge. between miR-890 and LINC00662 or ELK3. Long non-coding RNAs (LncRNAs) are a RESULTS: In the present study, it was demon- class of transcribed RNAs with a length of more strated that melanoma patients with high ex- 5-7 pression levels of LINC00662 had a shorter than 200 nucleotides and they participate in survival time than those with low expression lev- the regulation of various types of cancer by act- els of LINC00662. LINC00662 exhibited higher ing as a tumor promoter or suppressor8,9. In fact, expression levels in melanoma tissues and cell lncRNA PVT1 accelerates cell proliferation and lines. Additionally, suppression of LINC00662 invasion in gliomas by sponging miR-200a10. The impaired cell proliferation, migration, and inva- upregulation of lncRNA LINC00163 inhibits the sion. Furthermore, animal experiments demon- 11 strated that LINC00662 facilitated tumor growth development of lung cancer . LncRNA PICART1 in vivo. LINC00662 was confirmed to bind with represses cell proliferation and invasion in non- miR-890, and ELK3 was identified as a down- small cell lung cancer through affecting the stream target gene of miR-890. Furthermore, AKT1 signaling pathway12. Many lncRNAs are miR-890 was found to negatively regulate ELK3 also involved in the progression of melanomas. expression. Through rescue assays, overex- LncRNA CPS1-IT1 restrains melanoma cell me- pression of ELK3 reversed the inhibitive effects tastasis by competitively binding to BRG1 to sup- of LINC00662 knockdown or miR-890 mimics 13 on the cell proliferative, migratory, and invasive press Cyr61 . LncRNA RMEL3 enhances cell abilities. proliferation and tumor growth in melanoma14. CONCLUSIONS: Our results demonstrated LINC00662 is a novel lncRNA and acts as an on- that LINC00662 facilitated the occurrence and cogene in human cancers. For example, lncRNA development of melanoma by sponging miR- LINC00662 modulates the Hippo-YAP1 pathway 890 to upregulate ELK3. This discovery implied 15 that LINC00662 may be a promising prognos- to stimulate the progression of gastric cancer . tic and therapeutic biomarker for patients with LINC00662 acts as a competitive endogenous melanoma. RNA (ceRNA) to promote prostate cancer tum- Corresponding Author: Jun Chen, MD; e-mail: [email protected] 8429 X.-Q. Xia, W.-L. Lu, Y.-Y. Ye, J. Chen origenesis by regulating miR-34a expression16. NY, USA) and penicillin-streptomycin (penicil- However, the underlying molecular mechanisms lin: 100 UI/mL and streptomycin: 100 µg/mL; of LINC00662 in melanoma are unknown. Thermo Fisher Scientific, Waltham, MA, USA). Another important set of non-coding RNAs HEMa-LP cells were cultured in medium 254 are microRNAs (miRNAs), whose length is typ- (Thermo Fisher Scientific, Waltham, MA, USA) ically 18-24 nucleotides17,18. MiRNAs play im- and Human Melanocyte Growth Supplement-2 portant roles in the occurrence and development (HMGS-2; Thermo Fisher Scientific, Waltham, of various types of cancer, including melanoma. MA, USA). The cells were cultured at 37°C in an MiR-375 attenuates cell proliferation in esoph- atmosphere with 5% CO2. ageal squamous cell carcinoma by directly tar- The short-hairpin RNA against LINC00662 geting SP119. miR-485-5p suppresses cell prolif- (sh-LINC00662; 5’-GCUGCUGCCACU- eration in gliomas by directly targeting paired GUAAUAAUU-3’) with negative control (sh- box 320. MiR-338-5p targets CD82 to enhance NC; 5’-AAUUCUCGGAACGUCUGACGU-3’), the growth and metastasis of malignant melano- miR-890 mimics (5’- UACUUGGAAAGG- mas21. The miR-425/IGF-1 axis weakens mela- CAUCAGUUGtt-3’), miR-890 inhibitor (5’- noma metastasis by blocking the PI3K-Akt path- CAACUGAUGCCUUUCCAAGUAtt-3’) and way22. Recently, lncRNAs have been reported negative control (NC, 5’- AGACGUGUAUC- to act as ‘sponges’ to bind with miRNAs, which GUAACUGAUGtt- 3’) were synthesized by Ge- can regulate cancer. LncRNA small nucleolar nePharma (Shanghai, China). The full length of RNA host gene 1 (SNHG1) accelerates osteo- ELK3 was subcloned into pcDNA3.1 to overex- sarcoma progression by sequestrating miR-577 press ELK3 levels with empty pcDNA3.1 serving and activating the WNT2B/Wnt/β-catenin sig- as the control. The pcDNA3.1 vector was bought naling pathway23. LncRNA LINC00511 aggra- from GenePharma (Shanghai, China). The afore- vates breast cancer tumorigenesis by targeting mentioned plasmids were transfected into A375 the miR-185-3p/E2F1/Nanog axis24. LncRNA or SK-MEL-1 cells using Lipofectamine 2000 Re- DSCAM-AS1 contributes to the development of agent (Invitrogen, Carlsbad, CA, USA). melanomas by sponging miR-13625. In the pres- ent study, bioinformatics tools predicted that Real Time-Quantitative Polymerase Chain LINC00662 had the binding sequences for miR- Reaction (RT-qPCR) 890. miR-890 has been reported to attenuate TRIzol reagent (Invitrogen, Carlsbad, CA, triple-negative breast cancer progression26, but USA) was used according to the manufacturer’s its role in melanomas has not been investigated. protocol to isolate total RNA from melanoma As such, the present investigation further inves- cells. Total RNA was reverse transcribed into tigated the interaction between LINC00662 and cDNA using a PrimeScript RT reagent kit (Ta- miR-890 in melanoma. kara, Dalian, China). PCR amplification reaction In the present study, the role of LINC00662 was prepared using SYBR Green Real-Time PCR in melanoma was explored. It was confirmed that Master Mix (Thermo Fisher Scientific, Waltham, LINC00662 accelerated the progression of mela- MA, USA). The relative expression levels were noma by targeting the miR-890/ELK3 axis. calculated using the 2-ΔΔCq method. The expres- sion levels of LINC00662 or ELK3 were normal- ized to GAPDH. The expression levels of miR- Materials and Methods 890 were normalized to U6. The sequences of the primers were: LINC00662 forward, 5’-CAC- Cell Culture and Transfection GCTTCTGAAACTGGTGT-3’ and reverse, The normal human epidermal melanin cell 5’-TGTACAGCCTGGTGACAGAG-3’; miR-890 line, HEMa-LP, was acquired from Invitrogen forward, 5’-GCTTGGAAAGGCATCAGTTG-3’ (Carlsbad, CA, USA), and melanoma cell lines and reverse, 5’-CTCAACTGGTGTCGTG- including A375, SK-MEL-1, and SK-MEL-2 GAGTC-3’; ELK3 forward, 5’-ACCCAAAG- cells were purchased from the American Type GCTTGGAAATCT-3’ and reverse, 5’-TGTAT- Culture Collection (ATCC; Manassas, VA, GCTGGAGAGCAGTGG-3′; GAPDH forward, USA). Melanoma cells were incubated in Dul- 5’-ACCACAGTCCAT GCCATCAC-3’ and re- becco’s Modified Eagle’s Medium (DMEM; verse 5’-TCCACCACCCTGTTGCTGTA-3’; U6 Corning Life Sciences, MA, USA) with 10% forward, 5’-CTCGCTTCGGCAGCACAT-3’ and fetal bovine serum (FBS; Gibco, Grand Island, reverse, 5’-AACGCTTCACGAATTTGCGT-3’. 8430 LINC00662 promotes cell proliferation, migration and invasion of melanoma MTT Assay Animal Experiments Cell proliferation was measured using MTT Animal experiments were performed to deter- assays. Melanoma cells, at a density of 1x104 cells/ mine the impact of LINC00662 on tumor growth well, were cultured on 96-well plates. 10 μL MTT in vivo. The experiments were carried out on male (5 mg/ml; Bioswamp, Wuhan, China) was added BALB/C nude mice. Briefly, cells transfected into each well at the time of determination (0, 24, with sh-NC or sh-LINC00662 were injected into 48, and 72 h). Subsequently, dimethyl sulfoxide nude mice. Every 7 days, the volume and weight (~100 μl; Bio-Swamp, Wuhan, China) was then of tumors were calculated. 4 weeks later, mice added after incubation for 4 h. The optical density were sacrificed. The tumors were dissected and was measured at 450 nm using a microplate read- detected. The animal experiments were approved er (Bio-Rad, Hercules, CA, USA). by the Ethics Committee of Shanghai Ninth Peo- ple’s Hospital. Wound Healing Assay The transfected melanoma cells were seeded Statistical Analysis onto 6-well plates and cultured in standard con- Data are expressed as the mean ± SD and ditions until 80-90% confluent. A straight wound all experiments were repeated 3 times. Statis- was made using a sterile pipette tip. The size of tical analysis was conducted using the SPSS the wound was captured at 0 and 24 h using an 22.0 software (IBM Inc., Armonk, NY, USA). optical microscope (Leica DMI4000B, Milton Comparisons among the groups were tested us- Keynes, Bucks, UK) and the migration ratio was ing Student’s t-tests (for two groups) or one-way calculated. ANOVAs (for more than two groups) followed by Tukey’s test.
Load more

Recommended publications
  • Expression of Oncogenes ELK1 and ELK3 in Cancer
    Review Article Annals of Colorectal Cancer Research Published: 11 Nov, 2019 Expression of Oncogenes ELK1 and ELK3 in Cancer Akhlaq Ahmad and Asif Hayat* College of Chemistry, Fuzhou University, China Abstract Cancer is the uncontrolled growth of abnormal cells anywhere in a body, ELK1 and ELK3 is a member of the Ets-domain transcription factor family and the TCF (Ternary Complex Factor) subfamily. Proteins in this subfamily regulate transcription when recruited by SRF (Serum Response Factor) to bind to serum response elements. ELK1 and ELK3 transcription factors are known as oncogenes. Both transcription factors are proliferated in a different of type of cancer. Herein, we summarized the expression of transcription factor ELK1 and ELK3 in cancer cells. Keywords: ETS; ELK1; ELK3; Transcription factor; Cancer Introduction The ETS, a transcription factor of E twenty-six family based on a dominant ETS amino acids that integrated with a ~10-basepair element arrange in highly mid core sequence 5′-GGA(A/T)-3′ [1-2]. The secular family alter enormous 28/29 members which has been assigned in human and mouse and similarly the family description are further sub-divided into nine sub-families according to their homology and domain factor [3]. More importantly, one of the subfamily members such as ELK (ETS-like) adequate an N-terminal ETS DNA-binding domain along with a B-box domain that transmit the response of serum factor upon the formation of ternary complex and therefore manifested as ternary complex factors [4]. Further the ELK sub-divided into Elk1, Elk3 (Net, Erp or Sap2) and Elk4 (Sap1) proteins [3,4], which simulated varied proportional of potential protein- protein interactions [4,5].
    [Show full text]
  • Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model
    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A.
    [Show full text]
  • Seasonally Variant Gene Expression in Full-Term Human Placenta
    medRxiv preprint doi: https://doi.org/10.1101/2020.01.27.20018671; this version posted January 28, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Seasonally Variant Gene Expression in Full-Term Human Placenta Danielle A. Clarkson-Townsend1, Elizabeth Kennedy1, Todd M. Everson1, Maya A. Deyssenroth2, Amber A. Burt1, Ke Hao3, Jia Chen2, Machelle Pardue4,5, Carmen J. Marsit1* 1Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA 2Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA 3Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA 4Center for Visual and Neurocognitive Rehabilitation, Atlanta VA Healthcare System, Decatur, GA, USA 5Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA *Corresponding author Email: [email protected] 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.01.27.20018671; this version posted January 28, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. List of non-standard abbreviations BH = Benjamini and Hochberg DE = Differential expression FDR = False Discovery Rate FE = fall equinox SE = spring equinox SS = summer solstice WS = winter solstice 2 medRxiv preprint doi: https://doi.org/10.1101/2020.01.27.20018671; this version posted January 28, 2020.
    [Show full text]
  • To Luminal-Like Breast Cancer Subtype by the Small-Molecule
    Fan et al. Cell Death and Disease (2020) 11:635 https://doi.org/10.1038/s41419-020-02878-z Cell Death & Disease ARTICLE Open Access Triggering a switch from basal- to luminal-like breast cancer subtype by the small-molecule diptoindonesin G via induction of GABARAPL1 Minmin Fan1,JingweiChen1,JianGao 1,WenwenXue1,YixuanWang1, Wuhao Li1, Lin Zhou1,XinLi1, Chengfei Jiang2,YangSun1,XuefengWu1, Xudong Wu1,HuimingGe1,YanShen1 and Qiang Xu 1 Abstract Breast cancer is a heterogeneous disease that includes different molecular subtypes. The basal-like subtype has a poor prognosis and a high recurrence rate, whereas the luminal-like subtype confers a more favorable patient prognosis partially due to anti-hormone therapy responsiveness. Here, we demonstrate that diptoindonesin G (Dip G), a natural product, exhibits robust differentiation-inducing activity in basal-like breast cancer cell lines and animal models. Specifically, Dip G treatment caused a partial transcriptome shift from basal to luminal gene expression signatures and prompted sensitization of basal-like breast tumors to tamoxifen therapy. Dip G upregulated the expression of both GABARAPL1 (GABAA receptor-associated protein-like 1) and ERβ. We revealed a previously unappreciated role of GABARAPL1 as a regulator in the specification of breast cancer subtypes that is dependent on ERβ levels. Our findings shed light on new therapeutic opportunities for basal-like breast cancer via a phenotype switch and indicate that Dip G may serve as a leading compound for the therapy of basal-like breast cancer. 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; Introduction targets and the poor disease prognosis have fostered a Breast cancer is a heterogeneous disease comprised of major effort to develop new treatment approaches for different molecular subtypes, which can be identified patients with basal-like breast cancer.
    [Show full text]
  • ELK3 Mediated by ZEB1 Facilitates the Growth and Metastasis of Pancreatic Carcinoma by Activating the Wnt/Β-Catenin Pathway
    ELK3 Mediated by ZEB1 Facilitates the Growth and Metastasis of Pancreatic Carcinoma by Activating the Wnt/Β-Catenin Pathway Qiuyan Zhao Shanghai General Hospital Yingchun Ren Shanghai General Hospital Haoran Xie Shanghai General Hospital Lanting Yu Shanghai General Hospital Jiawei Lu Shanghai General Hospital Weiliang Jiang Shanghai General hospital Wenqin Xiao Shanghai General Hospital Zhonglin Zhu Henan Provincial People's Hospital Rong Wan Shanghai General Hospital Baiwen Li ( [email protected] ) Shanghai General Hospital Research Keywords: Pancreatic ductal adenocarcinoma, ELK3, EMT, Wnt/β-catenin, ZEB1 Posted Date: June 7th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-509276/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/31 Abstract Background Rapid progression and metastasis are the major cause of death of pancreatic ductal adenocarcinoma (PDAC) patients. ELK3, a member of ternary complex factor (TCF), has been associated with the initiation and progression of various cancers. However, the role of ELK3 in PDAC need to be further elucidated. Methods Online databases and immunohistochemistry were used to analyze ELK3 level in PDAC tissues. The function of ELK3 was conrmed by a series of in vivo and in vitro studies. Western blot and immunouorescence were used to detect the molecular mechanisms in PDAC. ChIP-qPCR was used to study the mechanism responsible for elevation of ELK3 in PDAC. Results ELK3 level was higher in PDAC tissues than that in adjacent normal tissues. Functionally, we demonstrated that ELK3 acted as an oncogene to promote PDAC tumorigenesis and metastasis. Further investigations suggested that ELK3 could promote PDAC cells migration and invasion by activating Wnt/ β-catenin pathway.
    [Show full text]
  • Engineered Type 1 Regulatory T Cells Designed for Clinical Use Kill Primary
    ARTICLE Acute Myeloid Leukemia Engineered type 1 regulatory T cells designed Ferrata Storti Foundation for clinical use kill primary pediatric acute myeloid leukemia cells Brandon Cieniewicz,1* Molly Javier Uyeda,1,2* Ping (Pauline) Chen,1 Ece Canan Sayitoglu,1 Jeffrey Mao-Hwa Liu,1 Grazia Andolfi,3 Katharine Greenthal,1 Alice Bertaina,1,4 Silvia Gregori,3 Rosa Bacchetta,1,4 Norman James Lacayo,1 Alma-Martina Cepika1,4# and Maria Grazia Roncarolo1,2,4# Haematologica 2021 Volume 106(10):2588-2597 1Department of Pediatrics, Division of Stem Cell Transplantation and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, USA; 2Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, USA; 3San Raffaele Telethon Institute for Gene Therapy, Milan, Italy and 4Center for Definitive and Curative Medicine, Stanford School of Medicine, Stanford, CA, USA *BC and MJU contributed equally as co-first authors #AMC and MGR contributed equally as co-senior authors ABSTRACT ype 1 regulatory (Tr1) T cells induced by enforced expression of interleukin-10 (LV-10) are being developed as a novel treatment for Tchemotherapy-resistant myeloid leukemias. In vivo, LV-10 cells do not cause graft-versus-host disease while mediating graft-versus-leukemia effect against adult acute myeloid leukemia (AML). Since pediatric AML (pAML) and adult AML are different on a genetic and epigenetic level, we investigate herein whether LV-10 cells also efficiently kill pAML cells. We show that the majority of primary pAML are killed by LV-10 cells, with different levels of sensitivity to killing. Transcriptionally, pAML sensitive to LV-10 killing expressed a myeloid maturation signature.
    [Show full text]
  • Xo PANEL DNA GENE LIST
    xO PANEL DNA GENE LIST ~1700 gene comprehensive cancer panel enriched for clinically actionable genes with additional biologically relevant genes (at 400 -500x average coverage on tumor) Genes A-C Genes D-F Genes G-I Genes J-L AATK ATAD2B BTG1 CDH7 CREM DACH1 EPHA1 FES G6PC3 HGF IL18RAP JADE1 LMO1 ABCA1 ATF1 BTG2 CDK1 CRHR1 DACH2 EPHA2 FEV G6PD HIF1A IL1R1 JAK1 LMO2 ABCB1 ATM BTG3 CDK10 CRK DAXX EPHA3 FGF1 GAB1 HIF1AN IL1R2 JAK2 LMO7 ABCB11 ATR BTK CDK11A CRKL DBH EPHA4 FGF10 GAB2 HIST1H1E IL1RAP JAK3 LMTK2 ABCB4 ATRX BTRC CDK11B CRLF2 DCC EPHA5 FGF11 GABPA HIST1H3B IL20RA JARID2 LMTK3 ABCC1 AURKA BUB1 CDK12 CRTC1 DCUN1D1 EPHA6 FGF12 GALNT12 HIST1H4E IL20RB JAZF1 LPHN2 ABCC2 AURKB BUB1B CDK13 CRTC2 DCUN1D2 EPHA7 FGF13 GATA1 HLA-A IL21R JMJD1C LPHN3 ABCG1 AURKC BUB3 CDK14 CRTC3 DDB2 EPHA8 FGF14 GATA2 HLA-B IL22RA1 JMJD4 LPP ABCG2 AXIN1 C11orf30 CDK15 CSF1 DDIT3 EPHB1 FGF16 GATA3 HLF IL22RA2 JMJD6 LRP1B ABI1 AXIN2 CACNA1C CDK16 CSF1R DDR1 EPHB2 FGF17 GATA5 HLTF IL23R JMJD7 LRP5 ABL1 AXL CACNA1S CDK17 CSF2RA DDR2 EPHB3 FGF18 GATA6 HMGA1 IL2RA JMJD8 LRP6 ABL2 B2M CACNB2 CDK18 CSF2RB DDX3X EPHB4 FGF19 GDNF HMGA2 IL2RB JUN LRRK2 ACE BABAM1 CADM2 CDK19 CSF3R DDX5 EPHB6 FGF2 GFI1 HMGCR IL2RG JUNB LSM1 ACSL6 BACH1 CALR CDK2 CSK DDX6 EPOR FGF20 GFI1B HNF1A IL3 JUND LTK ACTA2 BACH2 CAMTA1 CDK20 CSNK1D DEK ERBB2 FGF21 GFRA4 HNF1B IL3RA JUP LYL1 ACTC1 BAG4 CAPRIN2 CDK3 CSNK1E DHFR ERBB3 FGF22 GGCX HNRNPA3 IL4R KAT2A LYN ACVR1 BAI3 CARD10 CDK4 CTCF DHH ERBB4 FGF23 GHR HOXA10 IL5RA KAT2B LZTR1 ACVR1B BAP1 CARD11 CDK5 CTCFL DIAPH1 ERCC1 FGF3 GID4 HOXA11
    [Show full text]
  • Discerning the Role of Foxa1 in Mammary Gland
    DISCERNING THE ROLE OF FOXA1 IN MAMMARY GLAND DEVELOPMENT AND BREAST CANCER by GINA MARIE BERNARDO Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Dissertation Adviser: Dr. Ruth A. Keri Department of Pharmacology CASE WESTERN RESERVE UNIVERSITY January, 2012 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of Gina M. Bernardo ______________________________________________________ Ph.D. candidate for the ________________________________degree *. Monica Montano, Ph.D. (signed)_______________________________________________ (chair of the committee) Richard Hanson, Ph.D. ________________________________________________ Mark Jackson, Ph.D. ________________________________________________ Noa Noy, Ph.D. ________________________________________________ Ruth Keri, Ph.D. ________________________________________________ ________________________________________________ July 29, 2011 (date) _______________________ *We also certify that written approval has been obtained for any proprietary material contained therein. DEDICATION To my parents, I will forever be indebted. iii TABLE OF CONTENTS Signature Page ii Dedication iii Table of Contents iv List of Tables vii List of Figures ix Acknowledgements xi List of Abbreviations xiii Abstract 1 Chapter 1 Introduction 3 1.1 The FOXA family of transcription factors 3 1.2 The nuclear receptor superfamily 6 1.2.1 The androgen receptor 1.2.2 The estrogen receptor 1.3 FOXA1 in development 13 1.3.1 Pancreas and Kidney
    [Show full text]
  • The Hormone-Bound Vitamin D Receptor Regulates Turnover of Target
    The hormone-bound vitamin D receptor regulates turnover of target proteins of the SCFFBW7 E3 ligase By Reyhaneh Salehi Tabar Department of Experimental Medicine McGill University Montreal, QC, Canada April 2016 A thesis submitted to McGill University in partial fulfillment of the requirements of the degree of Doctor of Philosophy © Reyhaneh Salehi Tabar 1 Table of Contents Abbreviations ................................................................................................................................................ 7 Abstract ....................................................................................................................................................... 10 Rèsumè ....................................................................................................................................................... 13 Acknowledgements ..................................................................................................................................... 16 Preface ........................................................................................................................................................ 17 Contribution of authors .............................................................................................................................. 18 Chapter 1-Literature review........................................................................................................................ 20 1.1. General introduction and overview of thesis ............................................................................
    [Show full text]
  • 1 Transcriptomic Responses to Hypoxia in Endometrial and Decidual Stromal Cells 2 3 Kalle T
    bioRxiv preprint doi: https://doi.org/10.1101/2019.12.21.885657; this version posted December 23, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Transcriptomic responses to hypoxia in endometrial and decidual stromal cells 2 3 Kalle T. Rytkönen 1,2,3,4, Taija Heinosalo 1, Mehrad Mahmoudian 2,5, Xinghong Ma 3,4, Antti 4 Perheentupa 1,6, Laura L. Elo 2, Matti Poutanen 1 and Günter P. Wagner 3,4,7,8 5 6 1 Institute of Biomedicine, Research Centre for Integrative Physiology and Pharmacology, 7 University of Turku, Kiinamyllynkatu 10, 20014, Finland 8 2 Turku Bioscience Centre, University of Turku and Åbo Akademi University, Tykistökatu 6, 9 20520, Turku, Finland 10 3 Yale Systems Biology Institute, West Haven, Connecticut 06516, USA 11 4 Department of Ecology and Evolutionary Biology, Yale University, New Haven, CT 06511, 12 USA 13 5 Department of Future Technologies, University of Turku, FI-20014 Turku, Finland 14 6 Department of Obstetrics and Gynecology, Turku University Hospital, Kiinamyllynkatu 4-8, 15 20521, Turku, Finland. 16 7 Department of Obstetrics, Gynecology and Reproductive Sciences, Yale Medical School, New 17 Haven 06510, USA 18 8 Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI- 48201, USA 19 20 Correspondence should be addresses to K T Rytkönen; Email: [email protected]. Address: Institute 21 of Biomedicine, Research Centre for Integrative Physiology and Pharmacology, University of 22 Turku, Kiinamyllynkatu 10, 20014, Finland / Turku Bioscience Centre, University of Turku and 23 Åbo Akademi University, Tykistökatu 6, 20520, Turku, Finland.
    [Show full text]
  • Cell Density-Dependent Nuclear Accumulation of ELK3 Is Involved in Suppression of PAI-1 Expression
    CELL STRUCTURE AND FUNCTION 38: 145–154 (2013) © 2013 by Japan Society for Cell Biology Cell Density-dependent Nuclear Accumulation of ELK3 is Involved in Suppression of PAI-1 Expression Shu Tanaka1, Kazuyuki Nakao1, Toshihiro Sekimoto2, Masahiro Oka1,2, and Yoshihiro Yoneda1,2* 1Department of Frontier Biosciences, Graduate School of Frontier Biosciences, Osaka University, 1-3 Yamada-oka, Suita, Osaka 565-0871, Japan, 2Department of Biochemistry, Graduate School of Medicine, Osaka University, 1-3 Yamada-oka, Suita, Osaka 565-0871, Japan ABSTRACT. Cell-cell contact regulates the proliferation and differentiation of non-transformed cells, e.g., NIH/ 3T3 cells show growth arrest at high cell density. However, only a few reports described the dynamic behavior of transcription factors involved in this process. In this study, we showed that the mRNA levels of plasminogen activator inhibitor type 1 (PAI-1) decreased drastically at high cell density, and that ELK3, a member of the Ets transcription factor family, repressed PAI-1 expression. We also demonstrated that while ELK3 was distributed evenly throughout the cell at low cell density, it accumulated in the nucleus at high cell density, and that binding of DNA by ELK3 at the A domain facilitated its nuclear accumulation. Furthermore, we found that ETS1, a PAI-1 activator, occupied the ELK3-binding site within the PAI-1 promoter at low cell density, while it was released at high cell density. These results suggest that at high cell density, the switching of binding of transcription factors from ETS1 to ELK3 occurs at a specific binding site of the PAI-1 promoter, leading to the cell-density dependent suppression of PAI-1 expression.
    [Show full text]
  • MEF2 Transcription Factors Are Key Regulators of Sprouting Angiogenesis
    Downloaded from genesdev.cshlp.org on October 1, 2021 - Published by Cold Spring Harbor Laboratory Press MEF2 transcription factors are key regulators of sprouting angiogenesis Natalia Sacilotto,1,9 Kira M. Chouliaras,1,9 Leonid L. Nikitenko,1,8 Yao Wei Lu,2 Martin Fritzsche,1 Marsha D. Wallace,1 Svanhild Nornes,1 Fernando García-Moreno,3 Sophie Payne,1 Esther Bridges,4 Ke Liu,5 Daniel Biggs,6 Indrika Ratnayaka,1 Shane P. Herbert,7 Zoltán Molnár,3 Adrian L. Harris,4 Benjamin Davies,6 Gareth L. Bond,1 George Bou-Gharios,5 John J. Schwarz,2 and Sarah De Val1 1Ludwig Institute for Cancer Research Ltd., Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, United Kingdom; 2Center for Cardiovascular Sciences, Albany Medical College, Albany, New York 12208, USA; 3Department of Physiology, Anatomy, and Genetics, University of Oxford, Oxford OX1 3QX, United Kingdom; 4Department of Oncology, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 7LJ, United Kingdom; 5Institute of Aging and Chronic Disease, University of Liverpool, Liverpool L7 8TX, United Kingdom; 6The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, United Kingdom; 7Faculty of Life Sciences, University of Manchester, Manchester M13 9PT, United Kingdom Angiogenesis, the fundamental process by which new blood vessels form from existing ones, depends on precise spatial and temporal gene expression within specific compartments of the endothelium. However, the molecular links between proangiogenic signals and downstream gene expression remain unclear. During sprouting angiogen- esis, the specification of endothelial cells into the tip cells that lead new blood vessel sprouts is coordinated by vascular endothelial growth factor A (VEGFA) and Delta-like ligand 4 (Dll4)/Notch signaling and requires high levels of Notch ligand DLL4.
    [Show full text]